Company intelligence / Profile preview

成都恩沐生物科技

Chengdu, Sichuan, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Enmu Biotech is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the development of multi-specific antibodies for cancer immunotherapy. The company utilizes its proprietary Trite (Trispecific T-cell Engager) platform to create next-generation biologics that simultaneously target multiple tumor antigens and T-cell receptors. Its lead programs focus on hematologic malignancies, including bispecific and trispecific antibodies targeting CD19, CD20, and BCMA. In 2021, the company was acquired by Sino Biopharmaceutical to strengthen its oncology pipeline and biologics capabilities.

Therapeutic areas: Oncology
Modalities: Trispecific antibodyBispecific monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on 成都恩沐生物科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 成都恩沐生物科技.

Explore the full profile